Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Inhibitor
12-Oxocalanolide A is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 of 2.8 μM and an EC50 of 12 μM. This compound serves as an analogue of Calanolide, demonstrating significant antiviral activity against human immunodeficiency virus type 1. It is valuable for research in virology and the development of anti-HIV therapeutics. -
HIV Protease Inhibitor
CGP 53820 is a potent inhibitor of HIV protease, demonstrating Ki values of 9 nM for HIV-1 protease and 53 nM for HIV-2 protease. This compound effectively disrupts the enzymatic activity critical for the replication of HIV, making it a valuable tool in AIDS research and the study of antiretroviral therapies. Its specificity and efficacy support investigations into HIV resistance and the development of novel therapeutic strategies. -
HIV Inhibitor
HIV-1 Inhibitor-37 is a potent inhibitor of HIV-1, targeting viral replication pathways. It has demonstrated efficacy in reversing latency, presenting valuable potential for development as a novel therapeutic agent. This compound is suitable for research applications focused on HIV latency and the mechanisms of viral eradication. -
HIV-1 Capsid Protein Inhibitor
I-XW-053 sodium is an inhibitor of the HIV-1 capsid protein, demonstrating significant antiviral activity against HIV-189BZ167 with an IC50 value of 164.2 μM. This compound effectively disrupts the interaction between the N-terminal domains of the capsid protein, specifically at the NTD-NTD interface, exhibiting micromolar affinity. I-XW-053 is a valuable tool for research aimed at understanding HIV replication and developing therapeutic strategies against HIV infection. -
HIV-1 Capsid Inhibitor
HIV-1 Inhibitor-17 is a potent HIV-1 capsid inhibitor, demonstrating significant antiviral activity with an EC50 value of 2.57 μM against the HIV-1 NL4-3 strain. This compound exhibits certain cytotoxicity, with a CC50 value greater than 8.55 in MT-4 cells. It is valuable for research applications aimed at understanding HIV-1 replication and developing effective therapeutic strategies. -
Reverse Transcriptase Inhibitor
PNU-103657 is an orally active reverse transcriptase inhibitor, demonstrating an IC50 value of 0.51 μM against wild-type enzyme. This compound exhibits significant antiviral activity, making it a valuable tool in research targeting viral infections, particularly in the context of HIV and related immune system disorders. -
HIV-1 Reverse Transcriptase Inhibitor
DPC-082 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates significant antiviral activity, with an IC90 of 2.0 nM against wild-type RF virus. Additionally, DPC-082 effectively inhibits a variety of single and multiple amino acid substituted HIV-1 mutant strains, making it a valuable tool for research into HIV resistance mechanisms and therapeutic development. -
HIV Inhibitor
Fostemsavir sodium is an HIV-1 attachment inhibitor that demonstrates antiviral activity against multidrug-resistant strains of HIV-1. This compound not only hinders viral entry but also exhibits potential effects in reducing markers associated with monocyte activation and coagulation abnormalities. Its applications include research on HIV pathogenesis, treatment resistance, and the immune response in HIV-infected individuals. -
CCR5 inhibitor
CB-0821 is a high-affinity CCR5 inhibitor with a Ki value of 0.04 nM. It effectively binds to the hydrophobic pocket of the CCR5 protein, disrupting the interactions between viral proteins and CCR5, which inhibits viral entry into cells. This compound is poised for use in anti-HIV research applications, facilitating studies on viral tropism and potential therapeutic strategies. -
HIV-1 Protease Inhibitor
Mozenavir is a potent inhibitor of HIV-1 protease, exhibiting a Ki value of 0.3 nM. By obstructing the cleavage and processing of viral polyproteins, Mozenavir effectively inhibits the replication and maturation of HIV-1. This compound holds significant promise for advancing research on HIV infection and its associated therapeutic strategies. -
HIV Inhibitor
HIV-IN-13 is a potent HIV inhibitor that effectively targets the virus in CEM-SS cells with an EC50 of 1.38 μM. It exhibits antiviral activity against various HIV strains in human peripheral blood mononuclear cells (hPBMCs), demonstrating EC50 values ranging from 2.01 to 10.7 μM, while maintaining low cellular toxicity (TC50 > 100 μM). This compound is suitable for research applications focused on HIV infection and its mechanisms of action. -
HIV Inhibitor
HIV-1 inhibitor-57 is a potent HIV-1 inhibitor that targets reverse transcriptase (RT). Demonstrating activity against both wild-type and several prevalent non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, it exhibits effective EC50 values between 0.024 to 0.0010 μM. This compound enhances binding through additional interactions with critical residues in the HIV-1 RT binding site, making it a valuable tool for HIV research and antiviral drug development. -
Reverse Transcriptase Inhibitor
Niglizin is a noncompetitive inhibitor of reverse transcriptase, demonstrating significant efficacy in suppressing HIV replication. This compound exhibits a synergistic effect when used in conjunction with Zidovudine, enhancing its antiviral activity. Niglizin is valuable for research applications focused on HIV infection and the development of antiretroviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-31 is a potent inhibitor targeting the HIV-1 virus. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for AIDS research. Its effectiveness in inhibiting viral replication allows for the investigation of novel therapeutic approaches in the treatment of HIV infection. -
HIV-1 Inhibitor
Rhuscholide A is a benzofuran lactone that primarily inhibits HIV-1 activity. It exhibits significant antiviral potency, with an EC50 value of 1.62 μM. This compound is useful in research focused on the development of HIV therapies and studying viral replication mechanisms. -
HIV Inhibitor
Aureothin is a natural polyketide that functions as an HIV inhibitor, exhibiting an IC50 of 5.3 nM. This compound demonstrates significant antiviral activity, making it a valuable tool in HIV research. Additionally, Aureothin shows potential as a microbial biolarvicide, offering applications in ecological studies involving pest control and microbial interactions. -
HIV-1 Inhibitor
HIV-1 inhibitor-42 is a potent inhibitor of HIV-1 with an IC50 of 0.06 μM. This compound exerts its antiviral effects by targeting HIV-1 reverse transcriptase, inhibiting both RNA-dependent DNA polymerase and DNA-dependent DNA polymerase activities, with IC50 values of 0.518 μM and 0.072 μM, respectively. It serves as a valuable tool for studying HIV-1 replication and for the development of antiviral therapies. -
HIV-1 Inhibitor
HIV-IN peptide is a competitive inhibitor of HIV-1 protease, exhibiting an inhibitory constant (Ki) of 50 nM. This peptide plays a crucial role in the study of HIV-1 replication by disrupting the proteolytic processing of viral proteins. It is primarily utilized in research applications focused on antiviral drug development and the understanding of HIV biology. -
HIV-1 protease Inhibitor
U-96988 is a non-peptide inhibitor targeting HIV-1 protease, exhibiting a Ki value of 38 nM. It also demonstrates effectiveness against HIV-2 protease, with an IC50 value of 5 μM for the HIV-1IIIB strain. This compound serves as a valuable tool for research focused on HIV infection and protease inhibition mechanisms. -
HIV-1 Protease Inhibitor
Droxinavir is an HIV-1 protease inhibitor that specifically targets the S2 and S2' subsites of the HIV-1 protease enzyme. By binding to these sites, it interferes with the enzyme's function, preventing viral replication. The presence of the N88S mutation in the protease can confer resistance to Droxinavir, making it an important compound for investigating viral resistance mechanisms. This reagent is suitable for research applications related to human immunodeficiency virus type 1 infection and antiviral drug development. -
HIV-1 Protease Inhibitor
L-739594 is an HIV-1 protease inhibitor with a reported IC50 of 1.8 nM. It effectively inhibits the activity of the viral protease, impairing HIV replication. This compound is valuable for research applications aimed at studying HIV-1 biology and developing antiviral therapeutics. -
HIV-1 Fusion Inhibitor
Tifuvirtide (T-1249) is a synthetic peptide that acts as an HIV-1 fusion inhibitor by targeting the viral envelope glycoproteins to prevent entry into host cells. It exhibits potent antiretroviral activity, making it a valuable tool for studying HIV infection dynamics and therapeutic interventions. This compound is primarily utilized in research settings focused on HIV/AIDS pathogenesis and the development of novel antiviral strategies. -
HIV Inhibitor
(-)-Lentiginosine is an HIV inhibitor that targets viral replication mechanisms. This compound exhibits significant antiviral activity, making it a valuable tool in HIV research. Its unique structure and mode of action provide insights into potential therapeutic strategies for managing HIV infections. -
HIV-1 Attachment Inhibitor
BMS-585248 is a potent third-generation HIV-1 attachment inhibitor that interferes with the viral entry process. It demonstrates significant activity against HIV-1 and exhibits a favorable pharmacokinetic profile in both in vitro and in vivo studies. This compound is valuable for research applications aimed at developing novel therapeutic strategies for the treatment of HIV-1 infections. -
HIV-1 Protease Inhibitor
Hinnuliquinone is a dimeric non-peptide inhibitor of HIV-1 protease, characterized by its C2-symmetry. Isolated from the fungus Nodulisphorium hinnuleum, this bis-indolyl-2,5-dihydroxybenzoquinone is notable for its potent antiviral activity against HIV-1. It serves as a valuable tool in research applications focused on HIV treatment and protease inhibition studies. -
HIV-1 Inhibitor
HIV-1 inhibitor-19 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It effectively inhibits mutant strains, demonstrating EC50 values of 7.3 nM for L100I, 9.2 nM for K103N, and 21.0 nM for V106A/F227L variants. This compound is valuable for research applications aimed at understanding HIV resistance mechanisms and developing targeted antiviral therapies. -
HIV-1 Integrase Inhibitor
Kuwanon L is an inhibitor of HIV-1 integrase that effectively disrupts the interaction between HIV-1 integrase and LEDGF/p75, demonstrating IC50 values of 42 µM for LEDGF-dependent and 34 µM for LEDGF-independent integrase activity. With an IC50 of 22 µM for the integrase-LEDGF/p75 interaction, Kuwanon L also inhibits HIV-1 replication in immune cells. This compound is valuable for research focused on HIV-1 infection and the mechanisms underlying viral integration. -
HIV-1 Inhibitor
HIV-1 Inhibitor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase with an IC50 of 50 nM. This compound exhibits notable antiviral activity, demonstrating EC50 values between 2.22 and 53.3 nM against the HIV-1 IIIB strain and various mutant strains. It is valuable for research applications focused on HIV-1 mechanisms and the development of antiviral therapeutics. -
HIV Inhibitor
HIV Capsid Modulator 1 is a potent inhibitor targeting the HIV capsid protein. As a quinazolin-4-one-bearing phenylalanine derivative, it exhibits significant antiviral activity against both HIV-1 and HIV-2. This compound is primarily utilized in research applications aimed at understanding HIV replication and developing therapeutic strategies for HIV infection. -
HIV-1 Reverse Transcriptase Inhibitor
HI-280 is an HIV-1 reverse transcriptase inhibitor that disrupts the replication cycle of the virus. Its primary mechanism involves targeting the reverse transcriptase enzyme, critical for the transcription of viral RNA into DNA. HI-280 holds potential for research applications focused on the mechanisms of HIV infection and the development of antiretroviral therapies. -
HIV Inhibitor
Cyclotriazadisulfonamide hydrochloride is a selective CD4-targeted inhibitor that effectively blocks HIV entry and replication, specifically against HIV-1. By downregulating CD4 receptor expression on cell surfaces, it significantly impedes HIV transmission. This compound exhibits inhibitory activity against HIV-1 (NL4.3) and SIV (mac251) and demonstrates enhanced efficacy in combination with cellulose acetate (CAP). Additionally, it can be incorporated into microbial gel formulations to sustain CD4 downregulation and antiviral effects, marking it as a broad-spectrum agent against HIV. -
HIV Protease Inhibitor
P-1946 is a potent HIV protease inhibitor demonstrated to have a human HIV-1 protease Ki of 2.600 nM. It exhibits strong and selective in vitro antiviral activity, remaining effective against HIV isolates that have developed resistance to existing protease inhibitors. P-1946 is suitable for research applications focused on human immunodeficiency virus type 1 (HIV-1) infection. -
HIV Inhibitor
HIV-IN-2 is a potent inhibitor of HIV, targeting key viral processes essential for replication. This compound demonstrates significant antiviral activity, making it valuable for research applications in understanding HIV infection and its mechanisms. HIV-IN-2 offers potential insights for therapeutic strategies aimed at combatting HIV/AIDS. -
HIV Inhibitor
Tenofovir-C3-O-C15-CF3 ammonium is an innovative HIV inhibitor designed to enhance the pharmacokinetic properties over traditional tenofovir. This compound demonstrates significantly longer half-life (t1/2) values in human liver microsomes, along with potent anti-HIV activity in vitro. Its unique structure makes it a valuable candidate for research applications focused on developing more effective therapeutic strategies against HIV. -
Non-nucleoside Reverse Transcriptase Inhibitor
VRX-480773 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high specificity for HIV-1, demonstrating an EC50 of 0.14 nM against wild-type strains. This compound exhibits no inhibitory effects on HIV-2, HBV, or HCV, and does not affect human DNA polymerase α/β. Additionally, VRX-480773 maintains efficacy against Efavirenz-resistant HIV-1 variants, with EC50 values generally below 1 nM. Its unique properties make it a valuable tool for research into HIV/AIDS. -
HIV‑1 Protease Inhibitor
HIV-1-IN-88 is a potent HIV-1 protease inhibitor, demonstrating an IC50 value of 10 pM and an antiviral EC50 value of 10.4 nM. This compound retains efficacy against multidrug-resistant HIV-1 variants, including HIV-1Muta and HIV-1I50V, with EC50 values of 30.0 nM and 34.3 nM, respectively. HIV-1-IN-88 serves as a valuable tool for research aimed at understanding and combating HIV infection and resistance mechanisms. -
Non-nucleoside Reverse Transcriptase Inhibitor
HI-207 is a non-nucleoside reverse transcriptase inhibitor with demonstrated anti-HIV activity. It exhibits an IC50 value of 0.27 μM in PBMC/p24 inhibition assays, making it a potent candidate for studies investigating HIV infection mechanisms and therapeutic interventions. This compound is useful for researchers focusing on antiviral drug development and the modulation of HIV replication. -
HIV-1 Reverse Transcriptase Inhibitor
R-82150 is an HIV-1 reverse transcriptase inhibitor that functions by binding to the non-substrate binding site of the reverse transcriptase enzyme, effectively blocking the reverse transcription of viral RNA. This mechanism inhibits viral replication in HIV-1, while showing no effect on HIV-2, other RNA viruses, or DNA viruses. R-82150 is primarily utilized in research focused on understanding HIV-1 replication and therapeutic interventions. -
HIV-1 Inhibitor
CGP-75355 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 26 nM. This bis(L-tert-leucine) derivative effectively disrupts viral replication, making it a valuable tool for studying HIV-1 protease function and for the development of antiviral therapies. Its specificity and efficacy position CGP-75355 as a critical reagent in HIV research applications. -
HIV-1 Replication Inhibitor
DQBS is an inhibitor targeting the HIV-1 Nef protein, which plays a critical role in HIV replication. By binding to Nef, DQBS effectively inhibits the Nef-dependent processes essential for viral replication. This compound is valuable for research aimed at understanding HIV pathogenesis and developing therapeutic strategies to combat HIV infection. -
HIV Inhibitor
GSK-364735 potassium is a potent HIV integrase inhibitor, targeting the integrase enzyme of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM. This compound plays a crucial role in antiretroviral research by disrupting viral replication and integration processes. Its application extends to the development of therapeutic strategies against HIV, making it a valuable tool for researchers in the field of virology and infectious disease. -
Nucleoside Reverse Transcriptase Inhibitor
Lamivudine-13C,15N2 is a labeled impurity of Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). This compound effectively inhibits the reverse transcriptase activity of HIV-1 and HIV-2, as well as that of the hepatitis B virus, making it valuable in antiviral research. It is utilized in studies aiming to understand the pharmacokinetics and metabolic pathways of Lamivudine and its derivatives. -
HIV Inhibitor
CGP 57813 is a peptidomimetic inhibitor of HIV protease, designed to interfere with viral replication. This compound exhibits potential in therapeutic applications targeting HIV infection. Its ability to be encapsulated in nanoparticles made from poly(D,L-lactic acid) and pH-sensitive methacrylic acid copolymers enhances its delivery and stability within biological systems. -
HIV-1 Inhibitor
JTK-101 is a selective inhibitor of HIV-1, primarily targeting Tat cofactors such as CDK9 and cyclin T1. By inhibiting these cofactors, JTK-101 effectively reduces HIV-1 mRNA synthesis and suppresses the transcriptional activity of the virus. This compound is valuable for research applications focused on anti-HIV therapeutic strategies and understanding HIV transcription regulation. -
HIV-1 Inhibitor
L-708906 is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) with an IC50 value of 12 μM. This compound effectively inhibits HIV strains that are resistant to both nonnucleoside and nucleoside reverse transcriptase inhibitors. L-708906 is useful in research applications focused on the development of new therapeutic strategies for HIV treatment and resistance management. -
HIV Inhibitor
Salaspermic acid is a triterpene acid derived from Salacia macrosperma Wight, functioning as an inhibitor of HIV reverse transcriptase. This compound demonstrates significant antiviral activity by effectively reducing HIV replication in H9 lymphocyte cells. Salaspermic acid serves as a valuable tool for research focused on HIV pathogenesis and therapeutic development. -
HIV-1 Reverse Transcriptase Inhibitor
Mesoxalate, a dicarboxylic and ketonic acid, serves as an inhibitor of HIV-1 reverse transcriptase (RT). It exerts biological activity with an IC50 value of 2.2 μM, making it a valuable tool for studying the inhibition of HIV replication. Mesoxalate is applicable in research focusing on antiviral therapies targeting retroviral enzymes. -
HIV-1 Inhibitor
RDEA-427 is a pyrrolopyrimidine derivative that acts as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. This compound demonstrates efficacy against both wild-type and NNRTI-resistant mutant strains of HIV-1. RDEA-427 is suitable for research applications focused on HIV infection and the mechanisms of viral resistance. -
HIV-1 Reverse Transcriptase Inhibitor
L-702007 is a potent inhibitor of HIV-1 reverse transcriptase, a critical enzyme in the life cycle of the HIV virus. By obstructing viral replication, it exhibits significant antiviral activity, making it a valuable tool in HIV research. This compound is instrumental in studying the mechanisms of HIV infection and testing potential antiviral therapies. -
HIV Inhibitor
Adenallene is a nucleoside analogue that functions as an anti-HIV agent. It effectively inhibits the replication of both HIV-1 and HIV-2, demonstrating the ability to reduce cytopathic effects associated with these viruses. This compound is valuable for research focused on antiviral drug development and HIV pathogenesis studies.
